Thursday, 16 January 2020

Ophthalmic Suspension Industry Overview, Trends and Market Growth Analysis Research Report 2023

Ophthalmic Suspension Market Information: By Type of Content (Antibiotic, Antifungal, Antibacterial, Steroids, Nsaids and others), By Applications (Bacterial Infections, Retinal Disorders, Glaucoma, Allergies, Diabetic Eye Disease), By End Users (Hospitals, Eye Clinics, Pharmacies, and others) - Global Forecast till 2023
Market Scenario
The global ophthalmic suspension market is expected to exhibit a strong 6.8% CAGR over the forecast period from 2017 to 2023, according to the latest research report from Market Research Future (MRFR). The report profiles the leading players in the global ophthalmic suspension market to provide readers with a clear picture of the major drivers and restraints affecting the market growth over the forecast period. The global ophthalmic suspension market is also analyzed with respect to its segmentation in order to pinpoint the leading segments likely to drive the market’s progress over the coming years.
The suspension in the form of used to treat eye infections and related symptoms are generally termed as ophthalmic suspension. Generally it used in a combination of two such as antibiotics and a corticosteroid for more effective treatment. Various bacterial eye infections such as conjunctivitis are treated by ophthalmic suspension.   
Increasing prevalence of eye diseases across the globe is one of the major factors contributing to the growth of this ophthalmic suspension market size. Moreover, increasing geriatric population which are most prone to eye disorders, and growing number of bacterial infections cases in children will also boost the growth of the market. Furthermore, according to WHO (2014), glaucoma is the second major cause of blindness in the world which will increase the market growth.
On the other hand, the side-effects of ophthalmic suspension may hamper the market growth during the corresponding period.
Key Players 
  • Novartis AG (Alcon)
  • ALLERGAN
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Bausch & Lomb Incorporated
  • Falcon Group
  • Valeant
  • Bayer AG
  • Genentech, Inc.   
Segmentation
The global ophthalmic suspension market is segmented on the basis of type of content, which is segmented into antibiotic, antifungal, antibacterial, steroids, NSAIDs (non-steroidal anti-inflammatory drugs) and others.
On the basis of applications, it is segmented into bacterial infections, retinal disorders, glaucoma, allergies, diabetic eye disease, and others. Bacterial infection is further conjunctivitis, scleritis, and others. Retinal disorder is further segmented into macular degeneration, branch retinal vein occlusion, central retinal vein occlusion, congenital x-linked retinoschisis, and others.   
On the basis of end user, the market is segmented into hospitals, eye clinics, pharmacies, and others.
Regional Analysis
The American region accounted for the largest share of the global ophthalmic suspension market due to increasing prevalence of eye related diseases and increasing demand for new ophthalmic suspension for its treatment. Moreover, increasing geriatric population is another major factor responsible for the market growth in American countries.
In Asia Pacific, increasing government support for research & development in healthcare domain, growing number of ophthalmic clinics, and increasing prevalence of eye related diseases drives the growth of the market in this region.
Europe is the second largest ophthalmic suspension market across the globe owing to increasing awareness regarding eye related diseases, growing technological advancements in healthcare domain and increasing investment in healthcare domain by government.
The Middle East & Africa is expected to show a least market share due to less availability of medical facilities, and less development in healthcare domain.
Posted by at No comments:

Molecular Modelling Market Growth Opportunities, Analysis and Forecasts Report 2019-2023

Molecular Modelling Market Research Report: by Product (Software and Services), by Application (Drug Development, Drug Discovery, and Others), by End-user (Pharmaceutical & Biotechnology Companies, Research & Academic Centers) - Global Forecast Till 2023
Market Scenario
Molecular modelling comprises an array of computational techniques used in creation, manipulation, and representation of the various reactions and structures of molecules. Its applications included drug discovery and development but have since extended into computational chemistry and materials science. Rising use of molecular modelling by scientists to run multiple simulations can expedite the drug development process considerably.
The global molecular modelling market share is anticipated to expand at a 15.16% CAGR from 2018 to 2023 (forecast period), according to the latest report by Market Research Future (MRFR). Investments in R&D by pharmaceutical and biotechnology companies and prevalence of chronic diseases are factors certain to spur market growth over the forecast period.
According to the Brookings Private Sector Global Health R&D Project, nearly USD 159.9 Bn has been dispensed for healthcare R&D in developed and developing regions. Out of which, the majority can be credited to pharmaceutical companies. The booming biosimilars and biologics industry is bound to propel the market demand in the coming years. But the high R&D expenditure can impede market growth.
Report Overview
The report covers the latest trends affecting the market to provide the most accurate forecasts and predictions. By correlating the historical data with key market dynamics, our analysts make highly astute projections regarding the scope of the market and its future prospects. MRFR’s report includes a thorough analysis of the global molecular modelling market segmented by product, application, end-user, and region. Trends and opportunities are highlighted coupled with the market share of companies as well as their valuation in the market. It analyzes new revenue sources for players and outlines the various strategies implemented by players.
Segment Overview
Products in the molecular modelling market include software and services. Major applications include drug discovery, drug development, and others. Drug discovery is sub-segmented into direct drug design, indirect drug design, and molecular mimicry. End-users of the market include research centers and academic institutions, pharmaceutical and biotechnology companies, and others.
The segments covered in the report are analyzed with respect to four major regions – Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. The definition and advantages of “molecular modelling” is outlined in the report for a comprehensive understanding of the market. The report discusses in detail the various players and their respective strategies to enhance their value chain.
Competitive Landscape
Some of the key players in the molecular modelling market include Cresset, Acellera Ltd., Schrödinger, LLC, Optibrium, BioSolve-IT, Simulations Plus, Inc., Chemical Computing Group, Certara, L.P, OpenEye Scientific Software, Dassault Systèmes, Cambridge Crystallographic Data Centre, and others. New product launches and clinical trials are used to gauge the success of drugs. Various strategies such as acquisitions, partnerships, joint ventures, and distribution agreements are used by these players to gain a major share in the market.
The report offers comprehensive profiles on these market players and assesses their current standing in the market. Company history coupled with annual turnover, profit margins, segmental share, SWOT analysis, growth strategies, new product launches, mergers and acquisitions (M&A) activities, and latest R&D initiatives are discussed in granular detail.
Opportunity:
Countries situated near the equator have become the budding ground for many chronic diseases such as chagas, dengue, leprosy, and rabies due to problematic climactic conditions forcing these countries to employ the latest advancements into their system. Governments of developing countries have initiated education programs and projects such as the Janala Project in Bangladesh, ProjectABC in Nigeria, Tostan in Senegal, Yoza in South Africa, and BridgeIT in Tanzania, and others to create awareness regarding the conditions and healthcare IT tools.
Regional Analysis
The Americas dominates the global molecular modelling market owing to well-developed technology, increasing prevalence of the people suffering from cardiovascular diseases, and increasing government support for research & development. Furthermore, high healthcare expenditure and increasing R&D activities have fuelled the growth of the market in this region.
Europe holds the second position in the global molecular modelling market, which is followed by Asia Pacific. It is expected that the government support for research & development and availability of funds for research will drive the market. Asia Pacific is the fastest growing molecular modelling market due to the presence of rapidly growing economy, developing healthcare technology, increasing healthcare expenditure, and huge patient pool.
On the other hand, the Middle East & Africa holds the least share of the market due to limited availability of medical facilities, less availability of funds, and poor political conditions in Africa.
Posted by at No comments:

TMJ Disorders Market Growing prevalence of genetic disorder, Top Trends, Key Players Growth Analysis, Regional Opportunity, Market Share, Demand Overview 2019 – 2023

TMJ disorders market information: diagnosis (physical exam, imaging tests, and others), by treatment (medications, therapies, and others), by end user- global forecast till 2023
Market Synopsis of Global TMJ disorders Market
TMJ (temporomandibular joint and muscle) disorder is a medical condition which causes dysfunction and pain in the jaw joint and the muscles that control jaw movement. The medical condition is diagnosed more frequently in women than the men. According to the American Academy of Orofacial Pain, TMJ disorders may have more than one symptoms and causes. Some of the major symptoms of this disorder are aching facial pain, tenderness or pain in jaws, pain while chewing etc. TMJ disorders can occur if the joint's cartilage is damaged by arthritis or by a blow or other impact or the disk erodes or moves out of its proper alignment.
According to the recent study report published by the Market Research Future, global TMJ disorders market is booming and expected to gain prominence over the forecast period. The market is projected to demonstrate a sound growth by 2023, surpassing its previous growth records in terms of value with a striking CAGR during the anticipated period (2017 – 2023).
The major drivers will be the increasing prevalence of TMJ disorder, rising healthcare expenditures and growing awareness for the oral health.  According to the National Institute of Dental and Craniofacial Research in 2014, the prevalence of temporomandibular joint and muscle disorder (TMJD) was in between 5% to 12%. Moreover, according to the Centers for Medicare & Medicaid Services in 2016, the U.S. healthcare expenditure was about USD 3.3 trillion, which accounted for 17.9% of the total GDP within the same year.
However, lack of awareness and low per capita healthcare expenditure in the middle and low income countries may restrain the market growth during the forecast period.
North America leads the TMJ Disorders market share owing to well-developed healthcare infrastructure and rising per capita healthcare expenditure. Following the same trends Europe holds the second largest market share. Asia Pacific is the fastest growing region for the market due to the presence of the developed economies like India and China within the region. According to the Indian Brand Equity Foundation in 2017, Indian healthcare sector is one of the fastest growing industries which is expected to advance at a CAGR of 22.87% during 2015-20 and reach USD 280 billion by 2020.  However, Middle East and Africa holds the least market share in the global market. Presence of the stringent government policies and low per capita income in the African region restrains the market growth during the forecast period. On the other hand, Middle East leads the market of the Middle East & Africa region, due to the presence of developed economies like Kuwait and Qatar.
Global TMJ Disorders Market - Competitive Analysis
Characterized by the presence of several well-established and small players, the TMJ disorders market appears to be highly competitive and fragmented. International players are increasingly expanding their footprint in the developing economy, making it difficult for regional vendors to compete with them, especially in terms of features such as product differentiation, product portfolios, quality, and pricing.  The market is witnessing intensified competition which is expected to get more intensified further during the forecast period. The intense competition prevalent in the market dictates the consolidation among marketers.
Well established players incorporate acquisition, collaboration, partnership, expansion, and product launch in order to gain competitive advantage in this market and to maintain their market position.
Pfizer Inc. is a U.S. based biopharmaceutical company and plays a significant role in the TMJ disorders market. The company’s total revenue was about USD 52,824 million in 2016. Moreover, it was estimate that the company spent 14.9% of its total revenue in research and development which made the company to improve its position in the global market and enhance its product portfolio.
In August 2016, FDA approved Pfizer's TROXYCA ER extended-release capsules CII for pain management.
In March 2017, ALLERGAN announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURE XC, for correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.
AbbVie Inc. (US), Allergan (Republic of Ireland), Bayer AG (Germany), Bristol-Myers Squibb Company (US), Jubilant Cadista (US), Pfizer Inc. (US), and Sun Pharmaceutical Industries Ltd. (India) are some of the prominent players at the forefront of competition in the global TMJ disorders market and are profiled in MRFR Analysis.  Global TMJ Disorders Market - Regional Analysis
Browse Complete 80 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/check-discount/4090
Posted by at No comments:

Encephalomyelitis Market Growth Trends, Size Estimation, Industry Analysis, Sales Statistics, Global Share, Leading Key Players and Regional Forecast 2023

Encephalomyelitis Market Research Report–Type (Acute Disseminated Encephalomyelitis, Encephalomyelitis Disseminata, Antimog Associated, AIDS Related Encephalomyelitis), Treatment (Drug Treatment, Surgery), End User (Hospital) - Global Forecast till 2023                                                                                                                          
Market Scenario
Encephalomyelitis is brain or spinal cord inflammation caused due to virus, infections, and other foreign particles. The patient suffering from autoimmune diseases and AIDS are more prone to the diseases. A wide range of drugs are available for the treatment of this disease, however no precise treatment is available to cure the disease. Increasing prevalence of encephalomyelitis and autoimmune diseases has boosted the growth of the market. According to the WHO, 4.3 million people across the globe are affected by this disease. Additionally, changing lifestyle, increasing geriatric population, increasing need for better treatment has driven the global market. Moreover, increasing government support along with the per capita income have fuelled the market growth. However, limited and high cost of treatment options may retard the growth of the market over the assessment period.
The global encephalomyelitis market is expected to grow at a CAGR of ~8.1 % during the forecast period 2017-2023. 
Segmentations
The global encephalomyelitis market is segmented on the basis of types, treatment and end users.
On the basis of treatment, the market is segmented into drug treatment, plasmapheresis, surgery, and others. Drug therapy is further segmented into antiviral medications, antibiotics, steroids, sedatives, NSAIDs, mood stabilizers, and others.
On the basis of types, the market is segmented into acute disseminated encephalomyelitis, encephalomyelitis disseminata, antiMOG associated encephalomyelitis, equine encephalomyelitis, AIDS related encephalomyelitis and others.
On the basis of end users, the market is segmented into hospital, clinics and others.
Regional Analysis
The Americas command a major share of the market owing to the large patient population, growing prevalence of encephalomyelitis & autoimmune diseases, and strong government support for research & development. According to the American Autoimmune Related Diseases Association, approximately 50 million people in the U.S. were reported to be suffering from autoimmune diseases in 2014.
Europe accounts for the second largest market across the globe, which is followed by Asia Pacific. Strong government support, availability of funds for research and high healthcare expenditure drives the growth of the market. Asia Pacific is the fastest growing market. China, and India are the key contributors to the market growth due to presence of huge population base, increasing prevalence of AIDS and autoimmune diseases, rapidly growing economy, and increasing healthcare expenditure. Additionally, increasing government support, and presence of huge opportunity have fuelled the growth of the market in Asia Pacific.
The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition in African region. The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market owing to the well-developed economy and high healthcare spending.
Key Players
Some of key the players in the market are Bristol-Myers Squibb Company (U.S.), Sanofi (France), GlaxoSmithKline Plc. (U.K), Spectrum Pharmaceuticals Inc. (U.S.), Amgen, Inc. (U.S.), Merck & Co., Inc. (U.S.), Bayer AG (Germany), Novartis AG (Switzerland), F. Hoffmann-La Roche Ltd. (Switzerland), Eli Lilly and Company (U.S.), AstraZeneca Plc. (U.K), Janssen Biotech, Inc. (U.S.), AbbVie Inc. (U.S.), Takeda Pharmaceuticals (Japan), Immunomedics (U.S.), Pfizer, Inc. (U.S.), and Oncomed Pharmaceuticals (U.S.).
Posted by at No comments:

Medical Tricorder Market 2019 Business Trends, Regional Study, Size, Share, Industry Profit Growth and Global Segments by Forecast to 2023

Global Medical Tricorder Information, By Type (USB Camera, Fiber Optic Camera, Wireless, Corded, others), By Application (Diagnosis, Monitoring, others), By End Users (Hospitals, Clinics and others) - Forecast to 2023
Market Synopsis of Global Medical Tricorder Market
Medical device used by the consumer to self-diagnose medical condition is known as a medical tricorder. It takes basic vital measurement like heart rate and body temperature within seconds. Major functions of a medical tricorder are to monitor health of a person, summarize patient’s health, diagnose disease and take health measurements. Furthermore, rapid development in technology, increasing government support for research & development, changing lifestyle, and many adverse effects of the present diagnostic methods expected to fuel the market growth during the forecast period.
Medical Device Industry is flourishing across the globe owing to an increasing demand for technologically advanced devices, extensive use of smart medical devices, and overall improvement in healthcare sector. Various smart devices are used to determine the heart rate, glucose levels in the body, and other parameters.
Global medical tricorder market is expected to reach USD 5.4 billion in 2023 from USD 2.5 billion in 2016 with a CAGR of approximately 6.7% during the forecast period 2017-2023.
However, these types of devices has to pass all the regulatory standards and rules, which increases the approval time. The average approval time for the medical diagnostic device may vary from 5-8 years. This long approval time, high cost of the research & development and devices may hamper the market growth during the corresponding period.
The demand of medical tricorder is increasing because of an increase in the demand medical tricorder among health care providers, helping them to diagnose patient’s health condition, increasing outpatient services in the hospitals, increase in patient pool suffering from diabetes, and cardiovascular diseases, and demand for new technology for diagnoses and monitoring.
According to findings from the WHO, in 2014, approximately 422 million people suffered from diabetes across the globe.
Global Medical Tricorder Market – Regional:
Geographically, the regional market is segmented into America, Europe, Asia Pacific, and the Middle East & Africa.
America is the largest market which is attributed to extensive use of medical tricorder by number of physicians in America. Increasing in patient pool, increase in outpatient services and concentration of major market players of medical tricorder in North America drive this market in America. North America is the largest market whose growth is attributed to an increase in patient pool, and demand for improved technology for diagnosis of ongoing health of a patient drive this market in America. According to the American Diabetes Association, in 2015, approximately 30.3 million Americans which is 9.4% of the American population were suffering from diabetes 
The European market is also growing continuously and slowly catching up with the American market in the near future. Emphasis for early diagnosis of disease condition and awareness regarding the use of tricorder. Extensive research in innovative product development, and adoption of new technologies in healthcare institutes such as hospitals & clinics, research institutes, clinical laboratories, diagnostics center and home care settings. QuantuMDx Group Ltd. is in Europe. It is one of the major market players for medical tricorder, thus favoring the opportunities for research and development activities in the field of medical devices and molecular diagnosis.
Asia-Pacific market is expected to show steady growth in the medical tricorder market during the forecasted period owing to the rising prevalence of chronic diseases such as obesity, diabetes, cardiovascular diseases, growing geriatric population, and development in healthcare sector. China and India are expected to be the emerging market in Asia Pacific, owing to the increasing number of patients diagnosed with chronic diseases, and high growth potentials supported by favourable macro-economic conditions.
Middle East & Africa show slow growth in this market owing to demand for primary care services for the diagnosis and treatment of chronic diseases, and rising awareness about preventive measures for various diseases, and increasing emphasis on women and child care.
Global Medical Tricorder Market: Company Analysis
Ibis Biosciences, Inc. provides molecular diagnostics, offers instruments and reagents to analyze DNA and RNA for clinical specialists and laboratory. In February 2016, the company won a USD 2,124,718 federal contract from the Defense Advanced Research Projects Agency, Arlington, Virginia for R&D.
Posted by at No comments:

Urethritis Market Growth Trends, Size Estimation, Industry Analysis, Sales Statistics, Global Share, Leading Key Players and Regional Forecast 2023


According to Market Research Future, Urethritis Market is segmented By Type (Infective Urethritis (Non-Gonococcal, Gonococcal), Nonspecific Urethritis), By Diagnosis (Microbial Culture Tests), Drug Treatment (Pain Killers, Anti-Bacterial, Antivirals), By End.
Urethritis is an inflammation of the urethra, or the tube that carries urine. It shows various symptoms such as pain while urinating and an increased urge to urinate. Additionally, burning sensation while urinating, presence of blood in the semen or urine, frequent urge and discomfort while urinating, abnormal discharge from the vagina or penis, etc. are other common symptoms. Other serious manifestation of urethritis include damage to the reproductive system, pelvic inflammatory disease (PID), which can result in infertility, and others. The primary cause of urethritis is usually infection by bacteria, while viral infection for pre-existing sexually transmitted diseases being the secondary cause. Urethritis is also caused by mechanical or chemical damage to the urethra during treatment or catheterization. Urethritis should not be confused with urinary tract infection (UTI). Urethritis is an inflammation of the urethra, while a UTI is an infection of the urinary tract and both may have similar symptoms, but often require different treatment.
Urethritis Market is expected to reach USD 18.0 billion by 2023 at a CAGR of ~ 8.0 % during the forecast period 2019-2023.
Females have a greater chance of developing urethritis than males because of the nearness of urethra to the anus, which increases the chance of microbial infection. Also men’s urethras is much longer than women’s. According to the Centers for Disease Control and Prevention (CDC), causative organisms associated with urethritis include Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, Human papillomavirus (HPV),  Herpes simplex virus (HSV), and Cytomegalovirus (CMV) and others. According to Antimicrobe, Nongonococcal bacteria caused urethritis in approximately 4 million Americans in 2015 accounting for 80% of the cases. According to Department of Health, U.K., urethritis accounts for 0.005% of hospital consulting with a high 97% of hospital consulting for urethritis requiring hospital admission. Almost 20% of hospital admissions for urethritis requires an emergency.
Rising demand for the treatment due to growing population, increasing screening, rising number of geriatrics, rising safety and success of drug treatment, the extricating nature of the pain, and others are driving the growth of the market. However, complications of treatment such as side effects, emergence of bacterial resistance to antibiotics, cost of urethritis treatment, and others may hamper the market growth.
Key Players in the Global Urethritis Market
·         F. Hoffmann-La Roche AG,
·         GlaxoSmithKline,
·         AbbVie,
·         Johnson & Johnson, and Merck & Co.,
·         Eli Lilly and Company,
·         Bristol-Myers Squibb Company,
·         Bayer AG,
·         AstraZeneca plc. and others.
Segments
The global urethritis market has been segmented on the basis of types, diagnosis, drug treatment, and end user.
Based on the types, the market has been segmented as infective urethritis and nonspecific urethritis.
Based on the diagnosis, the market has been segmented as physical examination, microbial culture tests, and others.
Based on the drug treatment, the market has been segmented as pain killers, anti-bacterials, antivirals, and others.
Based on the end user, the market has been segmented as hospitals and clinics, research and academics, and others.
Global Urethritis Market Regional Analysis
The Americas accounts for a significant market share owing to high expenditure on the health care, especially, of the U.S. and Canada. Additionally, the greater number of hospitalization procedures due to greater healthcare penetration in the U.S. and Canada drives the urethritis market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates are adding fuel to the market growth. The consolidation of large healthcare players in the U.S. also leads the growth of the market due to increased  buying power of the healthcare players.
Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future urethritis market in the region.
Europe is the second largest market in the world due to growing healthcare industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to the large pharmaceutical industry.
Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa.
Browse More Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Posted by at No comments:

Diastematomyelia Market 2019 Global Size, Share, Top Leaders, Historical Analysis, Sales Revenue, Opportunities, Development Status, Competitive Landscape and Regional Forecast to 2023

Diastematomyelia Market Research Report: By Type (Dual Dural Sac, Single Sac), Host (Children, Adults), Therapy (Diagnosis (Imaging (MRI, CT), Prenatal Ultrasound), Treatment), End User (Hospital, Clinics, Ambulatory Centers) - Global Forecast till 2023                                                                                                                          
Market Scenario
Diastematomyelia is a rare anomaly resulting in the vertical splitting of the spinal cord. Females are more susceptible to this disease than males. According to the World Health Organization (2015), 1 in 2000 people suffers from this disease. However, during the last few years, the prevalence rate is increasing continuously. Increasing number of patients suffering from the disease, rising geriatric population and rising government support for research & development have driven the growth of the market. Moreover, rising demand for the better treatment, and changing lifestyle habits have fuelled the growth of the market. However, the cost of the surgery is too high and is not affordable to the people in developing region. Thus, the high cost of treatment may restrain the market.
A number of diagnostic procedures are available in the market for the diagnosis of the diastematomyelia. Increasing healthcare expenditure and rising government support have supported the growth of the market. According to the Boston Children's Hospital, in 2015, 5% of children across the globe were suffering from sustain spinal cord injuries. Furthermore, rapid development in the imaging technology and continuous improvement in the medical services have fuelled the market growth. The cost associated with the surgeries is very high which is not affordable for the people in developing region. Thus, high cost of surgeries, and lack of the precise treatment may restrain the growth of the diastematomyelia market.
The Global Diastematomyelia Market is expected to grow at a CAGR of 8.3% during forecast period 2017-2023.
Key players
The major key players in the global diastematomyelia market: 3M (US), GlaxoSmithKline PLC (U.K), Pfizer Inc. (U.S.), Lineage Medical, Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Bristol-Myers Squibb and Company (U.S.), B. Braun (Germany), Stryker Corporation (U.S.), Argon Medical Devices, Inc (the Netherlands), Cook Medical (U.S.)
SegmentationThe global diastematomyelia market is segmented on the basis of types, host, therapy, and end users.
On the basis of type, the market is segmented into dual dural sac (type 1), and single sac (type 2).
On the basis of host, the market is segmented into children and adults.
On the basis of therapy, the market is segmented into diagnosis & therapy. The diagnosis is further segmented into imaging techniques, and prenatal ultrasound. Imaging techniques are further categorised into Plain X-ray, CT, MRI and others. The therapy is further segmented into surgical intervention, scoliosis surgery, decompression (surgery), and others.
On the basis of end users, the market is segmented into hospital, clinics, ambulatory centers, and others.
Regional Analysis
Asia Pacific is the fastest growing region in the global diastematomyelia market owing to the presence of huge patient pool, rapidly developing economies, and increasing demand for the better treatment options. Majority of the market is driven by India and China owing to huge patient population.
The Americas dominates the global diastematomyelia market owing to large patient population. According to the Brain and Spinal Cord Injury Rehabilitation, in 2015, over 259,000 people in the U.S. were suffering from spinal cord injury. Increasing number of patients suffering from diastematomyelia and other spinal disease have driven the growth of the Americas diastematomyelia market. Additionally, high per capita income and increasing government support for research & development will fuelled the growth of the market. Diastematomyelia is considered as a rare diseases thus, government and other private companies are trying to create awareness among the people by conducting different seminars. Increasing awareness among people regarding the disease and well-developed technology will create opportunities for the development of the market.
Europe accounts for the second largest diastematomyelia market, which is followed by Asia Pacific. Availability of funds for research, huge geriatric population, and government support for research & development projected to drive the market in Europe. The U.K and Germany are the major contributors for the market.
Whereas, the Middle East & Africa owns the least share of the global diastematomyelia market due to the presence of poor economy, especially, in the Africa region. The market of this region is dominated by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure. However, Africa region shows the fastest growth for the market.
Posted by at No comments:
Labels:
Subscribe to: Posts (Atom)